Company Filing History:

10 out of 12,157

Bayer Aktiengesellschaft

patents

1 out of 832,680

Other

patents

Years Active: 1991-2006

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7115602 - Heterocycles 3 (2006-10-03),

2. 7087605 - 5-Ethyl-imidazotriazinones (2006-08-08),

3. 7074790 - 5-ethylimidarotriazones (2006-07-11),

4. 5872280 - Leukotriene antagonistic benzoic acid derivatives (1999-02-16),

5. 5374647 - Antithrombotic substituted cycloalkano (B) dihydroindole sulphonamides (1994-12-20),

6. 5332755 - Indole derivatives, a process for their preparation and their use in (1994-07-26),

7. 5246966 - Substituted alkenoic acid and its derivatives (1993-09-21),

8. 5204374 - Cycloalkano(b)dihydroindoles and -indolesulphonamides substituted by (1993-04-20),

9. 5118700 - Indole derivatives and compositions for their use in medicaments (1992-06-02),

10. 5096897 - Antithrombotic substituted cycloalkano(b)dihydroindole- and (1992-03-17),

11. 5039670 - Antithrombotic substituted cycloalkano(B)dihydroindole- and (1991-08-13),

Title: Celebrating the Innovations of Inventor Nigel J Cuthbert

Introduction: Nigel J Cuthbert, an accomplished inventor based in Great Missenden, GB, has made significant contributions to the field of medicinal chemistry. With a remarkable portfolio of 10 patents, Cuthbert focuses on developing innovative compounds aimed at treating inflammatory processes and immune diseases. His work not only demonstrates his expertise but also his dedication to advancing medical science.

Latest Patents: Among his latest inventions are the patents for heterocycles, specifically the 7-(4-tert butyl-cyclohexyl)-imidazotriazinones. This invention details novel processes for their preparation and explores their applications in medicaments designed to treat and prevent inflammatory conditions and immune diseases. Another noteworthy patent involves 5-Ethyl-imidazotriazinones, which similarly focuses on novel compounds and their potential uses in medical treatments.

Career Highlights: Nigel J Cuthbert's career is currently anchored at Bayer Aktiengesellschaft, a leading global pharmaceutical and biotechnology company. His work has contributed to the advancement of medicine, particularly in developing innovative treatments for complex diseases. His extensive experience in research and development has enabled him to play a pivotal role in his field.

Collaborations: Cuthbert works alongside esteemed colleagues such as Peter Norman and Hilary P Francis. Their collaborative efforts foster a creative environment, promoting breakthroughs in their shared pursuit of effective medical solutions. This teamwork exemplifies the importance of collaboration in scientific advancements.

Conclusion: Nigel J Cuthbert is a distinguished inventor whose work not only enhances our understanding of medicinal chemistry but also represents a beacon of hope for patients facing inflammatory and immune diseases. His dedication to innovation continues to inspire future generations of scientists and inventors, reinforcing the vital role of research in improving human health.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.